tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Jul 27;8(8)
fab352.
doi: 10.1093/ofid/ofab352. eCollection 2021 Aug.
Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity
James B O'Keefe[SUP] 1 [/SUP], H Caroline Minton[SUP] 2 [/SUP], Mary Morrow[SUP] 3 [/SUP], Colin Johnson[SUP] 4 [/SUP], Miranda A Moore[SUP] 5 [/SUP], Ghazala A D O'Keefe[SUP] 6 [/SUP], Karima Benameur[SUP] 7 [/SUP], Jason Higdon[SUP] 1 [/SUP], Jessica K Fairley[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Individuals with coronavirus disease 2019 (COVID-19) may have persistent symptoms following their acute illness. The prevalence and predictors of these symptoms, termed postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; PASC), have not been fully described.
Methods: Participants discharged from an outpatient telemedicine program for COVID-19 were emailed a survey (1-6 months after discharge) about ongoing symptoms, acute illness severity, and quality of life. Standardized telemedicine notes from acute illness were used for covariates (comorbidities and provider-assessed symptom severity). Bivariate and multivariable analyses were performed to assess predictors of persistent symptoms.
Results: Two hundred ninety patients completed the survey, of whom 115 (39.7%) reported persistent symptoms including fatigue (n = 59, 20.3%), dyspnea on exertion (n = 41, 14.1%), and mental fog (n = 39, 13.5%), among others. The proportion of persistent symptoms did not differ based on duration since illness (<90 days: n = 32, 37.2%; vs >90 days: n = 80, 40.4%; P = .61). Predictors of persistent symptoms included provider-assessed moderate-severe illness (adjusted odds ratio [aOR], 3.24; 95% CI, 1.75-6.02), female sex (aOR, 1.99; 95% CI, 0.98-4.04; >90 days out: aOR, 2.24; 95% CI, 1.01-4.95), and middle age (aOR, 2.08; 95% CI, 1.07-4.03). Common symptoms associated with reports of worse physical health included weakness, fatigue, myalgias, and mental fog.
Conclusions: Symptoms following acute COVID-19 are common and may be predicted by factors during the acute phase of illness. Fatigue and neuropsychiatric symptoms figured prominently. Select symptoms seem to be particularly associated with perceptions of physical health following COVID-19 and warrant specific attention on future studies of PASC.
Keywords: COVID-19; PASC; SARS-CoV-2; prolonged; symptoms.
. 2021 Jul 27;8(8)
fab352.doi: 10.1093/ofid/ofab352. eCollection 2021 Aug.
Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity
James B O'Keefe[SUP] 1 [/SUP], H Caroline Minton[SUP] 2 [/SUP], Mary Morrow[SUP] 3 [/SUP], Colin Johnson[SUP] 4 [/SUP], Miranda A Moore[SUP] 5 [/SUP], Ghazala A D O'Keefe[SUP] 6 [/SUP], Karima Benameur[SUP] 7 [/SUP], Jason Higdon[SUP] 1 [/SUP], Jessica K Fairley[SUP] 8 [/SUP]
Affiliations
- PMID: 34395709
- PMCID: PMC8360237
- DOI: 10.1093/ofid/ofab352
Abstract
Background: Individuals with coronavirus disease 2019 (COVID-19) may have persistent symptoms following their acute illness. The prevalence and predictors of these symptoms, termed postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; PASC), have not been fully described.
Methods: Participants discharged from an outpatient telemedicine program for COVID-19 were emailed a survey (1-6 months after discharge) about ongoing symptoms, acute illness severity, and quality of life. Standardized telemedicine notes from acute illness were used for covariates (comorbidities and provider-assessed symptom severity). Bivariate and multivariable analyses were performed to assess predictors of persistent symptoms.
Results: Two hundred ninety patients completed the survey, of whom 115 (39.7%) reported persistent symptoms including fatigue (n = 59, 20.3%), dyspnea on exertion (n = 41, 14.1%), and mental fog (n = 39, 13.5%), among others. The proportion of persistent symptoms did not differ based on duration since illness (<90 days: n = 32, 37.2%; vs >90 days: n = 80, 40.4%; P = .61). Predictors of persistent symptoms included provider-assessed moderate-severe illness (adjusted odds ratio [aOR], 3.24; 95% CI, 1.75-6.02), female sex (aOR, 1.99; 95% CI, 0.98-4.04; >90 days out: aOR, 2.24; 95% CI, 1.01-4.95), and middle age (aOR, 2.08; 95% CI, 1.07-4.03). Common symptoms associated with reports of worse physical health included weakness, fatigue, myalgias, and mental fog.
Conclusions: Symptoms following acute COVID-19 are common and may be predicted by factors during the acute phase of illness. Fatigue and neuropsychiatric symptoms figured prominently. Select symptoms seem to be particularly associated with perceptions of physical health following COVID-19 and warrant specific attention on future studies of PASC.
Keywords: COVID-19; PASC; SARS-CoV-2; prolonged; symptoms.